Ali Mosawi writes for Pharmaceutical Executive on the misconceptions of the country’s often inhospitable landscape, the essential role of international expertise in driving growth and how the sector has adapted to meet the challenges of the COVID-19 pandemic.
As companies consider the prospect of long-term disruption caused by the coronavirus, Ali Mosawi, chairman of leading Iraqi pharmaceutical
agent Al Hayat, provides an Expert View from 25 years of working in one of the world’s most misunderstood markets.
“The market is very stable, it’s surprising, the business is developing and increasing.”
Al Hayat has reported 35 per cent growth from 2017-2018 and 54 per cent from 2018-2019. In 2017, it won the representation of industry giants Pfizer, Madaus and MSD.
In 1974, my family and I were forced to flee Iraq. We made our new home in the UK, where we found happiness, fairness and opportunity. Even so, as time passed, it became apparent that while I had left Iraq, that country never left me.